"respiratory"

Ahead of the impending RSV season in September, Moderna’s mRNA-1345 and AstraZeneca’s Beyfortus are also likely to stake a claim in the market.

The findings showed that acute concentrations of fine particles, especially those smaller than 2.5 micrometres, cause inflammation of the respiratory, pulmonary and cardiovascular tracts and thicken the blood.